Atreleuton (Synonyms: A-85761.0, ABT-761, VIA-2291) |
| Catalog No.GC35425 |
A 5-LO inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 154355-76-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. 5-LO[1]
[1]. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc. [2]. Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. [3]. Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73.
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *